ILYRATOSI
Dead / Abandoned — Abandoned — no statement of use filed (as of 09 Oct 2025)
What this means for you
This application is over — abandoned 09 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97178382
- Mark type
- Stylized text
- Filed
- 17 Dec 2021
- Published for opposition
- 28 Jun 2022
- Abandoned
- 09 Oct 2025
- Attorney of record
- Douglas A. Rettew
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparation for the treatment of arthritis; anti-interleukin-6 (il-6) receptor monoclonal antibody for the treatment of disease caused by il-6 production; pharmaceutical preparations for the treatment of cytokine release syndrome; pharmaceutical preparations for the treatment of systemic sclerosis-associated interstitial lung disease
Owner
- BIOGEN INTERNATIONAL GMBH, BAAR, CH
- Biogen MA Inc., Cambridge, MA, US
- Biogen MA Inc., Cambridge, MA, US
Prosecution history
- 09 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 09 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 09 Apr 2025 — ASSIGNED TO EXAMINER
- 17 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Jul 2024 — SOU EXTENSION 4 GRANTED
- 17 Jul 2024 — SOU EXTENSION 4 FILED
- 17 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 30 May 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 30 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Nov 2023 — SOU EXTENSION 3 GRANTED
- 29 Nov 2023 — SOU EXTENSION 3 FILED
- 29 Nov 2023 — SOU TEAS EXTENSION RECEIVED
- 16 Aug 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Aug 2023 — SOU EXTENSION 2 GRANTED
- 14 Aug 2023 — SOU EXTENSION 2 FILED